Nevada
|
NeoGenomics,
Inc.
|
74-2897368
|
(State or Other Jurisdiction of Incorporation or
Organization)
|
(Name of Registrant in Our Charter)
|
(I.R.S. Employer Identification No.)
|
Robert P. Gasparini
|
||
12701 Commonwealth Drive, Suite 9
|
12701 Commonwealth Drive, Suite 9
|
|
Fort Myers, Florida 33913
|
Fort Myers, Florida 33913
|
|
(239) 768-0600
|
8731
|
(239) 768-0600
|
(Address and Telephone Number
of Principal Executive Offices and
Principal Place of Business)
|
(Primary Standard Industrial
Classification Code Number)
|
(Name, Address and Telephone Number
of Agent for Service)
|
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
(Do not check if a smaller reporting company)
|
Smaller
reporting company x
|
|
|||||||||||||
Title Of Each Class
Of Securities To Be Registered
|
Amount
To Be
Registered(1)
|
Proposed
Maximum
Offering Price
Per Share(2)
|
Maximum
Aggregate
Offering
Price(2)
|
Amount
Of Registration Fee (3)
|
|||||||||
Common
Stock, par value $0.001
per
share
|
6,500,000 shares
|
$
|
0.70
|
$
|
4,550,000
|
$
|
179
|
||||||
TOTAL
|
6,500,000
shares
|
$
|
0.70
|
$
|
4,550,000
|
$
|
179
|
||||||
(1)
|
The
shares of our common stock being registered hereunder are being registered
for sale by the selling stockholders named in the prospectus.
|
(2)
|
Estimated
solely for the purpose of calculating the registration fee pursuant to
Rule 457(c) under the Securities Act of 1933. For the purposes of this
table, we have used the average of the closing bid and asked prices as of
January 21, 2009.
|
(3)
|
Previously
paid.
|
PROSPECTUS
SUMMARY
|
1
|
|
THE
OFFERING
|
4
|
|
SUMMARY
CONSOLIDATED FINANCIAL INFORMATION
|
6
|
|
RISK
FACTORS
|
10
|
|
FORWARD-LOOKING
STATEMENTS
|
21
|
|
SELLING
STOCKHOLDERS
|
22
|
|
THE
FUSION TRANSACTION
|
23
|
|
USE
OF PROCEEDS
|
26
|
|
PLAN
OF DISTRIBUTION
|
27
|
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
28
|
|
DESCRIPTION
OF BUSINESS
|
40
|
|
MANAGEMENT
|
49
|
|
PRINCIPAL
STOCKHOLDERS
|
56
|
|
MARKET
PRICE OF AND DIVIDENDS ON THE REGISTRANT’S COMMON EQUITY AND OTHER
STOCKHOLDER MATTERS
|
59
|
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
|
60
|
|
DESCRIPTION
OF CAPITAL STOCK
|
62
|
|
LEGAL
MATTERS
|
64
|
|
EXPERTS
|
64
|
|
AVAILABLE
INFORMATION
|
64
|
|
CONSOLIDATED
FINANCIAL STATEMENTS OF NEOGENOMICS, INC.
|
F-i
|
a)
|
cytogenetics
testing, which analyzes human
chromosomes;
|
b)
|
Fluorescence
In-Situ Hybridization (“FISH”)
testing, which analyzes abnormalities at the chromosomal and gene
levels;
|
c)
|
flow
cytometry testing, which analyzes gene expression of specific markers
inside cells and on cell surfaces;
and
|
d)
|
molecular
testing which involves analysis of DNA and RNA to diagnose and predict the
clinical significance of various genetic sequence
disorders.
|
For the twelve months ended
December 31
|
FY 2007
|
FY 2006
|
% Inc
(Dec)
|
|||||||
Customer
Requisitions Received (Cases)
|
16,385
|
9,563
|
71.3
|
%
|
||||||
Number
of Tests Performed
|
20,998
|
12,838
|
63.6
|
%
|
||||||
Average
Number of Tests/Requisition
|
1.28
|
1.34
|
(4.5
|
%)
|
||||||
Total
Testing Revenue
|
$
|
11,504,725
|
$
|
6,475,996
|
77.7
|
%
|
||||
Average
Revenue/Requisition
|
$
|
702.15
|
$
|
677.19
|
3.7
|
%
|
||||
Average
Revenue/Test
|
$
|
547.90
|
$
|
504.44
|
8.6
|
%
|
For the nine months ended
September 30
|
FY 2008
|
FY 2007
|
% Inc
(Dec)
|
|||||||
Customer
Requisitions Received (Cases)
|
17,758
|
11,123
|
59.7
|
%
|
||||||
Number
of Tests Performed
|
23,049
|
14,332
|
60.8
|
%
|
||||||
Average
Number of Tests/Requisition
|
1.31
|
1.29
|
1.6
|
%
|
||||||
Total
Testing Revenue
|
$
|
14,094,959
|
$
|
7,709,408
|
82.8
|
%
|
||||
Average
Revenue/Requisition
|
$
|
802.77
|
$
|
693.01
|
15.8
|
%
|
||||
Average
Revenue/Test
|
$
|
611.52
|
$
|
537.91
|
13.7
|
%
|
· |
Aspen
Select Healthcare, LP (“Aspen”),
which intends to sell up to 2,130,364 shares of common stock previously
issued and sold by the Company to Aspen on April 15, 2003 (the
“2003 Aspen
Placement”).
Aspen received registration rights with respect to these shares
and therefore, such shares are being registered
hereunder.
|
· |
Mary
S. Dent, the spouse of Dr. Michael Dent, who is our Chairman of the Board
and founder, who intends to sell up to 553,488 shares of common stock
previously issued and sold by the Company to Dr. Dent as founder shares.
Such shares were subsequently transferred to Mary Dent in February 2007.
Dr. Dent received registration rights with respect to these shares and
therefore, such shares are being registered
hereunder.
|
· |
Those
shareholders other than Aspen and Mary Dent who are set forth in the
section herein entitled “Selling Stockholders” who intend to sell up to an
aggregate of 398,648 shares of common stock which they received in a
distribution from Aspen in September 2007. All of such shares were
originally purchased by Aspen in the 2003 Aspen Placement. Aspen received
registration rights with respect to these shares and has assigned such
rights to these selling stockholders and therefore, such shares are being
registered hereunder.
|
Common Stock
Offered
|
6,500,000
shares by selling stockholders
|
|
Offering
Price
|
Market
price
|
|
Common Stock Currently
Outstanding
|
32,122,382
shares as of January 21, 2009
|
|
Use of
Proceeds
|
We
will not receive any proceeds of the shares offered by the selling
stockholders. See “Use of Proceeds”.
|
|
Risk
Factors
|
The
securities offered hereby involve a high degree of risk. See “Risk
Factors” beginning on page 10 for a discussion of these
risks.
|
|
Over-the-Counter Bulletin Board Symbol
|
NGNM.OB
|
For the Nine Months Ended
|
|||||||
September 30,
|
September 30,
|
||||||
2008
|
2007
|
||||||
Net
Revenue
|
$
|
14,094,959
|
$
|
7,709,408
|
|||
Cost
of Revenue
|
6,577,549
|
3,623,860
|
|||||
Gross
Profit
|
7,517,410
|
4,085,548
|
|||||
Other Operating
Expenses:
|
|||||||
General
and administrative
|
7,706,284
|
5,664,053
|
|||||
Interest
expense, net
|
199,336
|
205,806
|
|||||
Total
Operating Expenses
|
7,905,620
|
5,869,859
|
|||||
Net
Loss
|
$
|
(388,210
|
)
|
$
|
(1,784,311
|
)
|
|
Net
Loss Per Share - Basic And Fully Diluted
|
$
|
(0.01
|
)
|
$
|
(0.06
|
)
|
|
Weighted
Average Number Of Shares Outstanding – Basic and Fully
Diluted
|
31,414,065
|
29,221,778
|
As of
|
||||||||||
September 30,
|
December 31,
|
|||||||||
2008
|
2007
|
|||||||||
Current
Assets
|
|
|||||||||
Cash
and cash equivalents
|
$
|
631,365
|
$
210,573
|
|||||||
Accounts
receivable (net of allowance for doubtful accounts of $283,111 and
$414,548, respectively)
|
3,381,066
|
3,236,751
|
||||||||
Inventories
|
344,608
|
304,750
|
||||||||
Other
current assets
|
900,146
|
400,168
|
||||||||
Total
current assets
|
5,257,185
|
4,152,242
|
||||||||
Property
and equipment (net of accumulated depreciation of $1,374,942 and $862,030,
respectively)
|
2,495,146
|
2,108,083
|
||||||||
Other
assets
|
275,087
|
260,575
|
||||||||
Total
Assets
|
$
|
8,027,418
|
$
6,520,900
|
|||||||
Liabilities And Stockholders’
Equity:
|
||||||||||
Current
Liabilities
|
||||||||||
Accounts
payable
|
$
|
1,904,694
|
$
1,799,159
|
|||||||
Accrued
expenses and other liabilities
|
955,405
|
1,319,580
|
||||||||
Revolving
credit line
|
1,176,221
|
-
|
||||||||
Short-term
portion of equipment capital leases
|
449,776
|
242,966
|
||||||||
Total
current liabilities
|
4,486,096
|
3,361,705
|
||||||||
Long Term
Liabilities
|
||||||||||
Long-term
portion of equipment capital leases
|
1,054,321
|
837,081
|
||||||||
Total
Liabilities
|
5,540,417
|
4,198,786
|
||||||||
Stockholders’
Equity
|
||||||||||
Common
stock, $.001 par value, (100,000,000 shares authorized; 31,686,355 and
31,391,660 shares issued and outstanding, respectively)
|
31,686
|
31,391
|
||||||||
Additional
paid-in capital
|
17,373,756
|
16,820,954
|
||||||||
Accumulated
deficit
|
(14,918,441
|
)
|
(14,530,231)
|
|||||||
Total
stockholders’ equity
|
2,487,001
|
2,322,114
|
||||||||
Total
Liabilities and Stockholders’ Equity
|
$
|
8,027,418
|
$
6,520,900
|
For the Years Ended
December 31,
|
|||||||
2007
|
2006
|
||||||
Net
Revenue
|
$
|
11,504,725
|
$
|
6,475,996
|
|||
Cost
of Revenue
|
5,522,775
|
2,759,190
|
|||||
Gross
Profit
|
5,981,950
|
3,716,806
|
|||||
Other Operating
Expense:
|
|||||||
General
and administrative
|
9,122,922
|
3,576,812
|
|||||
Income
/ (Loss) from Operations
|
(3,140,972
|
)
|
139,994
|
||||
Other Income /
(Expense):
|
|||||||
Other
income
|
24,256
|
55,.970
|
|||||
Interest
expense
|
(263,456
|
)
|
(325,625
|
)
|
|||
Other
income / (expense) – net
|
(239,200
|
)
|
(269,655
|
)
|
|||
Net
Loss
|
$
|
(3,380,172
|
)
|
$
|
(129,661
|
)
|
|
Net
Loss Per Share – Basic and Diluted
|
$
|
(0.11
|
)
|
$
|
(0.00
|
)
|
|
Weighted
Average Number of Shares Outstanding – Basic and
|
|||||||
Diluted
|
29,764,289
|
26,166,031
|
As of
|
|||||||
December 31,
2007
|
December 31,
2006
|
||||||
Assets:
|
|||||||
Cash
and cash equivalents
|
$
|
210,573
|
$
|
126,266
|
|||
Accounts
receivable (net of allowance for doubtful accounts of $414,548 and
103,463, respectively)
|
3,236,751
|
1,549,758
|
|||||
Inventories
|
304,750
|
117,362
|
|||||
Other
current assets
|
400,168
|
102,172
|
|||||
Total
current assets
|
4,152,242
|
1,895,558
|
|||||
Property
and equipment (net of accumulated depreciation of $862,030 and $494,942,
respectively)
|
2,108,083
|
1,202,487
|
|||||
Other
assets
|
260,575
|
33,903
|
|||||
Total
Assets
|
$
|
6,520,900
|
$
|
3,131,948
|
|||
Liabilities & Stockholders’
Equity:
|
|||||||
Current
Liabilities
|
|||||||
Account
payable
|
$
|
1,799,159
|
$
|
697,754
|
|||
Accrued
compensation
|
370,496
|
133,490
|
|||||
Accrued
expenses and other liabilities
|
574,084
|
67,098
|
|||||
Legal
contingency
|
375,000
|
-
|
|||||
Due
to affiliates (net of discount of $39,285)
|
-
|
1,635,715
|
|||||
Short-term
portion of equipment capital leases
|
242,966
|
94,430
|
|||||
Total
current liabilities
|
3,361,705
|
2,628,487
|
|||||
Long-Term
Liabilities
|
|||||||
Long-term
portion of equipment capital leases
|
837,081
|
448,947
|
|||||
Total
Liabilities:
|
4,198,786
|
3,077,434
|
|||||
Commitments
and contingencies
|
|||||||
Stockholders’
Equity:
|
|||||||
Common
Stock, $0.01 par value, (100,000,000 shares authorized;
And
31,391,660 and 27,061,476 shares issued and outstanding
at
December 31, 2007 and 2006, respectively)
|
31,391
|
27,061
|
|||||
Additional
paid-in capital
|
16,820,954
|
11,300,135
|
|||||
Deferred
stock compensation
|
-
|
(122,623
|
)
|
||||
Accumulated
deficit
|
(14,530,231
|
)
|
(11,150,059
|
)
|
|||
Total
stockholders’ equity
|
2,322,114
|
54,514
|
|||||
Total
Liabilities and Stockholders’ Equity
|
$
|
6,520,900
|
$
|
3,131,948
|
|||
· |
pricing
differences between our fee schedules and the reimbursement rates of
the payors;
|
· |
disputes
with payors as to which party is responsible for payment;
and
|
· |
disparity
in coverage and information requirements among various
carriers.
|
· |
With
a price of less than $5.00 per
share;
|
· |
That
are not traded on a “recognized” national
exchange;
|
· |
Whose
prices are not quoted on the Nasdaq automated quotation
system;
|
· |
Nasdaq
stocks that trade below $5.00 per share are deemed a “penny stock” for
purposes of Section 15(b)(6) of the Exchange
Act;
|
· |
In
issuers with net tangible assets less than $2.0 million (if the issuer has
been in continuous operation for at least three years) or $5.0 million (if
in continuous operation for less than three years), or with average
revenues of less than $6.0 million for the last three
years.
|
· |
Broker/dealers
dealing in penny stocks are required to provide potential investors with a
document disclosing the risks of penny stocks. Moreover, broker/dealers
are required to determine whether an investment in a penny stock is a
suitable investment for a prospective investor. These requirements may
reduce the potential market for our common stock by reducing the number of
potential investors. This may make it more difficult for investors in our
common stock to sell shares to third parties or to otherwise dispose of
them. This could cause our stock price to
decline.
|
Selling Stockholders
|
Shares Beneficially
Owned Before
Offering(1)
|
Percentage of
Outstanding
Shares
Beneficially
Owned Before
Offering(1)
|
Shares To Be
Sold In The
Offering
|
Percentage of
Outstanding
Shares
Beneficially
Owned After
The Offering
|
|||||||||
Fusion
Capital Fund II, LLC(2)
|
417,500
|
1.3
|
%
|
3,417,500
|
0.0
|
%
|
|||||||
Aspen
Select Healthcare, LP(3)
|
11,815,220
|
33.6
|
%
|
2,130,364
|
26.9
|
%
|
|||||||
Mary
S. Dent(4)
|
2,642,130
|
8.1
|
%
|
553,488
|
6.0
|
%
|
|||||||
Steven
C. Jones(5)
|
13,055,386
|
36.7
|
%
|
238,826
|
29.3
|
%
|
|||||||
Jones
Network, LP(6)
|
107,143
|
*
|
|
107,143
|
0.0
|
%
|
|||||||
Marvin
E. Jaffe(7)
|
63,096
|
*
|
|
21,429
|
*
|
|
|||||||
Steven
C. Jones ROTH IRA(8)
|
20,450
|
*
|
|
18,750
|
*
|
|
|||||||
Peter
M. Peterson(9)
|
11,926,862
|
33.8
|
%
|
12,500
|
25.6
|
%
|
|||||||
Total(10):
|
16,257,280
|
44.9
|
%
|
6,500,000
|
35.7
|
%
|
*
|
Less
than one percent (1%).
|
(1)
|
Applicable
percentage of ownership is based on 32,117,237 shares of our common stock
outstanding as of December 31, 2008, together with securities exercisable
or convertible into shares of common stock within sixty (60) days of
December 31, 2008, for each stockholder. Beneficial ownership
is determined in accordance with the rules of the SEC and generally
includes voting or investment power with respect to
securities. Shares of common stock are deemed to be
beneficially owned by the person holding such securities for the purpose
of computing the percentage of ownership of such person, but are not
treated as outstanding for the purpose of computing the percentage
ownership of any other person. Note that affiliates are subject
to Rule 144 and insider trading regulations - percentage computation is
for form purposes only.
|
(2)
|
Steven
G. Martin and Joshua B. Scheinfeld, the principals of Fusion Capital, are
deemed to be beneficial owners of all of the shares of common stock owned
by Fusion Capital. Messrs. Martin and Scheinfeld have shared voting and
disposition power over the shares being offered under this prospectus. As
of the date hereof, 417,500 shares of our common stock have been
previously acquired by Fusion Capital, consisting of 400,000 shares we
issued to Fusion Capital as a commitment fee and 17,500 shares that were
issued as an expense reimbursement. The Company may elect in its sole
discretion to sell to Fusion Capital up to an additional 3,000,000 shares
under the Purchase Agreement. Fusion Capital does not presently
beneficially own those shares as determined in accordance with the rules
of the SEC.
|
(3)
|
Aspen
Select Healthcare, LP (“Aspen”)
has direct ownership of 6,238,279 shares and has certain warrants to
purchase 3,050,000 shares, all of which are currently
exercisable. Aspen’s beneficial ownership also includes
2,526,941 shares to which Aspen has received a voting
proxy. The general partner of Aspen is Medical Venture
Partners, LLC, an entity controlled by Steven C. Jones and Peter M.
Peterson.
|
(4)
|
Mary
S. Dent is the spouse of Dr. Michael T. Dent, our chairman and founder.
Mrs. Dent has direct ownership of 1,202,471 shares which she received in a
spousal transfer from Dr. Dent in February 2007. Mrs. Dent’s beneficial
ownership also includes (i) 900,000 shares held in a trust for the benefit
of Dr. Dent’s children (of which Dr. Dent and his attorney are the sole
trustees), (ii) warrants exercisable by Dr. Dent within 60 days of
December 31, 2008 to purchase 139,659 shares and (iii) options exercisable
by Dr. Dent within 60 days of December 31, 2008 to purchase 400,000
shares.
|
(5)
|
Steven
C. Jones is the Acting Principal Financial Officer of the Company and a
member of the Company’s Board of Directors. Mr. Jones and his spouse have
direct ownership of 724,826 shares. Mr. Jones also has warrants
exercisable within 60 days of December 31, 2008 to purchase an additional
93,965 shares. Mr. Jones’ beneficial ownership also includes
(i) 107,143 shares owned by Jones Network, LP, a family limited
partnership that Mr. Jones controls, (ii) 250,000 warrants exercisable
within 60 days of December 31, 2008 owned by Aspen Capital Advisors, LLC,
a company that Mr. Jones controls, (iii) 32,475 warrants exercisable
within 60 days of December 31, 2008 owned by Gulf Pointe Capital, LLC, a
company that Mr. Jones and Mr. Peterson control and (iv) 31,757 shares
held in certain individual retirement and custodial
accounts. In addition, as a managing member of the general
partner of Aspen, he has the right to vote all shares controlled by Aspen,
thus all Aspen shares and currently exercisable warrants have been
included in his beneficial ownership totals (see Note 3). The shares to be
sold in this offering were received in a distribution from
Aspen.
|
(6)
|
Jones
Network, LP is a family limited partnership controlled by Steven C. Jones.
The shares to be sold in this offering were received in a distribution
from Aspen.
|
(7)
|
Marvin
Jaffe is a member of the Company’s Board of Directors and has direct
ownership of 21,429 shares and warrants exercisable within 60 days of
December 31, 2008 to purchase 41,667 shares. The shares to be sold in this
offering were received in a distribution from
Aspen.
|
(8)
|
The
shares being sold in this offering were received in a distribution from
Aspen.
|
(9)
|
Peter
M. Peterson is a member of the Company’s board of directors and has direct
ownership of 12,500 shares and warrants exercisable within 60 days of
December 31, 2008 to purchase an additional 66,667 shares. In addition, as
a managing member of the general partner of Aspen, he has the right to
vote all shares controlled by Aspen, thus all Aspen shares and currently
exercisable warrants have been added to his beneficial ownership totals
(see Note 3). Mr. Peterson’s beneficial ownership also includes
32,475 warrants exercisable within 60 days of December 31, 2008 owned by
Gulf Pointe Capital, LLC, a company that Mr. Jones and Mr. Peterson
control. The shares to be sold in this offering were received in a
distribution from Aspen.
|
(10) |
The
total number of shares listed does not double count the shares that may be
beneficially attributable to more than one person.
|
•
|
the
lowest sale price of our common stock on the purchase date;
or
|
•
|
the
average of the three lowest closing sale prices of our common stock during
the twelve consecutive business days prior to the date of a purchase by
Fusion Capital.
|
•
|
the
effectiveness of the registration statement of which this prospectus is a
part of lapses for any reason (including, without limitation, the issuance
of a stop order) or is unavailable to Fusion Capital for sale of our
common stock offered hereby and such lapse or unavailability continues for
a period of 20 consecutive business days or for more than an aggregate of
60 business days in any 365-day
period;
|
•
|
suspension
by our principal market of our common stock from trading for a period of
three consecutive business days;
|
•
|
the
de-listing of our common stock from our principal market provided our
common stock is not immediately thereafter trading on the American Stock
Exchange, the Nasdaq Global Market, the Nasdaq Capital Market, the Nasdaq
Global Select Market or the New York Stock
Exchange;
|
•
|
the
transfer agent‘s failure for five business days to issue to Fusion Capital
shares of our common stock which Fusion Capital is entitled to under the
Purchase Agreement;
|
•
|
any
material breach of the representations or warranties or covenants
contained in the Purchase Agreement or any related agreements which has or
which could have a material adverse effect on us subject to a cure period
of five business days; or
|
•
|
any
participation or threatened participation in insolvency or bankruptcy
proceedings by or against us; or
|
• |
a
material adverse change in our business;
|
Assumed Average
Purchase Price
|
Number of Shares to be
Sold if Full Purchase
|
Percentage of Outstanding
Shares After Giving Effect to the
Issuance to Fusion Capital(1)
|
Proceeds from the Sale of Shares
to Fusion Capital Under the
Purchase Agreement
|
|||
$0.45
|
3,000,000
|
8.5%
|
$1,350,000
|
|||
$0.69(2)
|
3,000,000
|
8.5%
|
$2,070,000
|
|||
$1.00
|
3,000,000
|
8.5%
|
$3,000,000
|
|||
$1.50
|
3,000,000
|
8.5%
|
$4,500,000
|
|||
$2.00
|
3,000,000
|
8.5%
|
$6,000,000
|
|||
$2.50
|
3,000,000
|
8.5%
|
$7,500,000
|
|||
$2.67
|
3,000,000
|
8.5%
|
$8,000,000
|
(1)
|
The
denominator is based on 32,117,237 shares outstanding as of December 31,
2008, which includes the 417,500 shares previously issued to Fusion
Capital. The numerator is based on the number of shares issuable under the
Purchase Agreement at the corresponding assumed purchase price set forth
in the adjacent column.
|
(2)
|
Closing
sale price of our shares on January 21,
2009.
|
|
•
|
ordinary
brokers’ transactions;
|
|
•
|
transactions
involving cross or block trades;
|
|
•
|
through
brokers, dealers, or underwriters who may act solely as agents
|
|
•
|
“at
the market” into an existing market for the common stock;
|
|
•
|
in
other ways not involving market makers or established business markets,
including direct sales to purchasers or sales effected through agents;
|
|
•
|
in
privately negotiated transactions; or
|
|
•
|
any
combination of the foregoing.
|
·
|
Revenue
Recognition
|
·
|
Accounts
Receivable
|
·
|
Accounting
For Contingencies
|
·
|
Stock
Based Compensation
|
December 31,
2007
|
|||||||||||||||||||||||||||||||||||||
Payor
Group
|
0-30
|
%
|
30-60
|
%
|
60-90
|
%
|
90-120
|
%
|
> 120
|
%
|
Total
|
%
|
|||||||||||||||||||||||||
Client
|
$
|
159,649
|
4
|
%
|
$
|
148,909
|
4
|
%
|
$
|
200,073
|
5
|
%
|
$
|
69,535
|
2
|
%
|
$
|
122,753
|
3
|
%
|
$
|
700,919
|
19
|
%
|
|||||||||||||
Commercial
Insurance
|
427,876
|
12
|
%
|
184,761
|
5
|
%
|
126,477
|
3
|
%
|
66,922
|
2
|
%
|
487,387
|
13
|
%
|
1,293,423
|
35
|
%
|
|||||||||||||||||||
Medicaid
|
918
|
0
|
%
|
904
|
0
|
%
|
2,331
|
0
|
%
|
1,292
|
0
|
%
|
11,892
|
0
|
%
|
17,337
|
0
|
%
|
|||||||||||||||||||
Medicare
|
662,560
|
18
|
%
|
293,870
|
8
|
%
|
94,755
|
3
|
%
|
70,579
|
2
|
%
|
486,002
|
13
|
%
|
1,607,766
|
44
|
%
|
|||||||||||||||||||
Self
Pay
|
9,745
|
0
|
%
|
6,324
|
0
|
%
|
6,889
|
0
|
%
|
3,238
|
0
|
%
|
5,658
|
0
|
%
|
31,854
|
1
|
%
|
|||||||||||||||||||
Total
|
$
|
1,260,748
|
34
|
%
|
$
|
634,768
|
17
|
%
|
$
|
430,525
|
12
|
%
|
$
|
211,566
|
6
|
%
|
$
|
1,113,692
|
31
|
%
|
$
|
3,651,299
|
100
|
%
|
December 31,
2006
|
|||||||||||||||||||||||||||||||||||||
Payor
Group
|
0-30
|
%
|
30-60
|
%
|
60-90
|
%
|
90-120
|
%
|
> 120
|
%
|
Total
|
%
|
|||||||||||||||||||||||||
Client
|
$
|
146,005
|
9
|
%
|
$
|
150,698
|
10
|
%
|
$
|
79,481
|
5
|
%
|
$
|
8,606
|
1
|
%
|
$
|
33,827
|
2
|
%
|
$
|
418,617
|
27
|
%
|
|||||||||||||
Commercial
Insurance
|
133,333
|
8
|
%
|
105,464
|
7
|
%
|
58,026
|
4
|
%
|
48,847
|
3
|
%
|
35,248
|
2
|
%
|
380,918
|
24
|
%
|
|||||||||||||||||||
Medicaid
|
325
|
0
|
%
|
650
|
0
|
%
|
2,588
|
0
|
%
|
400
|
0
|
%
|
-
|
0
|
%
|
3,963
|
0
|
%
|
|||||||||||||||||||
Medicare
|
293,298
|
19
|
%
|
282,463
|
18
|
%
|
71,283
|
5
|
%
|
68,830
|
4
|
%
|
56,598
|
4
|
%
|
772,472
|
49
|
%
|
|||||||||||||||||||
Self
Pay
|
135
|
0
|
%
|
2,058
|
0
|
%
|
723
|
0
|
%
|
-
|
0
|
%
|
-
|
0
|
%
|
2,916
|
0
|
%
|
|||||||||||||||||||
Total
|
$
|
573,096
|
36
|
%
|
$
|
541,333
|
35
|
%
|
$
|
212,101
|
13
|
%
|
$
|
126,683
|
8
|
%
|
$
|
125,673
|
8
|
%
|
$
|
1,578,886
|
100
|
%
|
Request Date
|
Completion Date
|
Shares of
Common
Stock
|
Gross
Proceeds
|
Yorkville
Fee
|
Escrow Fee
|
Net
Proceeds
|
ASP(1)
|
|||||||||||||||
8/29/2005
|
9/8/2005 |
63,776
|
$
|
25,000
|
$
|
1,250
|
$
|
500
|
$
|
23,250
|
||||||||||||
12/10/2005
|
12/18/2005 |
241,779
|
50,000
|
2,500
|
500
|
47,000
|
||||||||||||||||
Subtotal –
2005
|
305,555
|
$
|
75,000
|
$
|
3,750
|
$
|
1,000
|
$
|
70,250
|
$
|
0.25
|
|||||||||||
7/19/2006
|
7/28/2006 |
83,491
|
53,000
|
2,500
|
500
|
50,000
|
||||||||||||||||
8/8/2006
|
8/16/2006 |
279,486
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
10/18/2006
|
10/23/2006 |
167,842
|
200,000
|
10,000
|
500
|
189,500
|
||||||||||||||||
Subtotal –
2006
|
530,819
|
$
|
503,000
|
$
|
25,000
|
$
|
1,500
|
$
|
476,500
|
$
|
0.95
|
|||||||||||
12/29/2006
|
1/10/2007 |
98,522
|
150,000
|
7,500
|
500
|
142,000
|
||||||||||||||||
1/16/2007
|
1/24/2007 |
100,053
|
150,000
|
7,500
|
500
|
142,000
|
||||||||||||||||
2/1/2007
|
2/12/2007 |
65,902
|
100,000
|
5,000
|
500
|
94,500
|
||||||||||||||||
2/19/2007
|
2/28/2007 |
166,611
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
2/28/2007
|
3/7/2007 |
180,963
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
4/5/2007
|
4/16/2007 |
164,777
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
4/20/2007
|
4/30/2007 |
173,467
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
Subtotal –
2007
|
950,295
|
$
|
1,400,000
|
$
|
70,000
|
$
|
3,500
|
$
|
1,326,500
|
$
|
1.48
|
|||||||||||
Total Since
Inception
|
1,786,669
|
$
|
1,978,000
|
$
|
98,750
|
$
|
6,000
|
$
|
1,873,250
|
$
|
1.19
|
(1)
|
Average
Selling Price of shares issued.
|
a)
|
cytogenetics
testing, which analyzes human
chromosomes;
|
b)
|
Fluorescence
In-Situ Hybridization (“FISH”)
testing, which analyzes abnormalities at the chromosomal and gene
levels;
|
c)
|
flow
cytometry testing, which analyzes gene expression of specific markers
inside cells and on cell surfaces;
and
|
d)
|
molecular
testing which involves analysis of DNA and RNA to diagnose and predict the
clinical significance of various genetic sequence
disorders.
|
For the twelve months ended
December 31
|
FY 2007
|
FY 2006
|
% Inc
(Dec)
|
|||||||
Customer
Requisitions Received (Cases)
|
16,385
|
9,563
|
71.3
|
%
|
||||||
Number
of Tests Performed
|
20,998
|
12,838
|
63.6
|
%
|
||||||
Average
Number of Tests/Requisition
|
1.28
|
1.34
|
(4.5
|
)%
|
||||||
Total
Testing Revenue
|
$
|
11,504,725
|
$
|
6,475,996
|
77.7
|
%
|
||||
Average
Revenue/Requisition
|
$
|
702.15
|
$
|
677.19
|
3.7
|
%
|
||||
Average
Revenue/Test
|
$
|
547.90
|
$
|
504.44
|
8.6
|
%
|
For the nine months ended
September 30
|
FY 2008
|
FY 2007
|
% Inc
(Dec)
|
|||||||
Customer
Requisitions Received (Cases)
|
17,758
|
11,123
|
59.7
|
%
|
||||||
Number
of Tests Performed
|
23,049
|
14,332
|
60.8
|
%
|
||||||
Average
Number of Tests/Requisition
|
1.31
|
1.29
|
1.6
|
%
|
||||||
Total
Testing Revenue
|
$
|
14,094,959
|
$
|
7,709,408
|
82.8
|
%
|
||||
Average
Revenue/Requisition
|
$
|
802.77
|
$
|
693.01
|
15.8
|
%
|
||||
Average
Revenue/Test
|
$
|
611.52
|
$
|
537.91
|
13.7
|
%
|
Name
|
Age
|
Position
|
||
Board of
Directors:
|
||||
Robert
P. Gasparini
|
53
|
President
and Chief Science Officer, Board Member
|
||
Steven
C. Jones
|
45
|
Acting
Principal Financial Officer, Board Member
|
||
Michael
T. Dent
|
43
|
Chairman
of the Board
|
||
George
G. O’Leary
|
46
|
Board
Member
|
||
Peter
M. Peterson
|
52
|
Board
Member
|
||
Marvin
E. Jaffe
|
72
|
Board
Member
|
||
William
J. Robison
|
73
|
Board
Member
|
||
Other
Executives:
|
||||
Robert
J. Feeney
|
40
|
Vice
President of Business Development
|
||
Matthew
William Moore
|
34
|
Vice
President of Research and Development
|
||
Jerome
J. Dvonch
|
40
|
Principal
Accounting Officer
|
Name and
Principal Position
|
Year
|
Salary
|
Bonus
|
Stock
Award
|
Option
Award(1)
|
Non-
Equity
Incentive
Plan
Compen-
sation
|
Non-
qualified
Deferred
Compen-
sation
Earnings
|
All Other
Compen-
sation
|
Total
|
|||||||||||||||||||
Robert
P. Gasparini
|
2007
|
$
|
209,061
|
$
|
10,000
|
$
|
-
|
$
|
46,000
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
265,061
|
|||||||||||
President and Chief
|
2006
|
183,500
|
-
|
-
|
18,271
|
-
|
-
|
-
|
201,771
|
|||||||||||||||||||
Science
Officer
|
||||||||||||||||||||||||||||
Robert
J. Feeney
|
2007
|
161,192
|
12,375
|
-
|
39,593
|
-
|
-
|
-
|
213,160
|
|||||||||||||||||||
V.P. of
Business
|
2006
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||
Development
|
||||||||||||||||||||||||||||
Matthew
W. Moore
|
2007
|
167,221
|
-
|
-
|
9,534
|
-
|
-
|
-
|
176,755
|
|||||||||||||||||||
V. P. of
Research
|
2006
|
66,635
|
-
|
-
|
3,884
|
-
|
-
|
-
|
70,519
|
|||||||||||||||||||
and
Development
|
||||||||||||||||||||||||||||
Jerome
J. Dvonch
|
2007
|
123,077
|
6,000
|
-
|
31,759
|
-
|
-
|
-
|
160,836
|
|||||||||||||||||||
Principal
|
2006
|
92,846
|
-
|
-
|
4,936
|
-
|
-
|
-
|
97,782
|
|||||||||||||||||||
Accounting
Officer
|
||||||||||||||||||||||||||||
Steven
C. Jones
|
2007
|
-
|
-
|
-
|
-
|
-
|
-
|
127,950
|
(2)
|
127,950
|
||||||||||||||||||
Acting Principal Financial
|
2006
|
-
|
-
|
-
|
-
|
-
|
-
|
71,000
|
(2)
|
71,000
|
||||||||||||||||||
Officer and
Director
|
(1)
|
See
Note F to our Consolidated Financial Statements included herein for a
description on the valuation methodology of stock option awards. Pursuant
to Regulation SK, Item 402, Paragraph (c)(2)(v), amounts indicated are the
portion of the grant date fair value of options that are recognized under
SFAS 123 (R) for the year
indicated.
|
(2)
|
Mr.
Jones acts as a consultant to the Company and the amounts indicated
represent the consulting expense accrued for the periods indicated for his
services as our Acting Principal Financial
Officer.
|
Name and
Principal Position
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
|
Equity Incentive
Plan Awards-Number of
Securities
Underlying
Unexercised &
Unearned
Options
|
Option
Exercise
Price
|
Option
Expiration
Date
|
|||||||||||
Robert
P. Gasparini
|
635,000
|
-
|
-
|
0.25
|
1/1/2015
|
|||||||||||
President and Chief
|
100,000
|
-
|
-
|
1.47
|
2/13/2017
|
|||||||||||
Science
Officer
|
||||||||||||||||
Robert
J. Feeney
|
34,375
|
221,875
|
-
|
1.50
|
12/31/2016
|
|||||||||||
V.P. of
Business
|
||||||||||||||||
Development
|
||||||||||||||||
Matthew
W. Moore
|
25,000
|
62,500
|
-
|
0.71
|
8/1/2016
|
|||||||||||
V.P. of
Research
|
8,125
|
-
|
-
|
1.47
|
2/13/2017
|
|||||||||||
and
Development
|
||||||||||||||||
Jerome
J. Dvonch
|
26,650
|
6,000
|
-
|
0.37
|
7/28/2015
|
|||||||||||
Principal
|
11,667
|
23,333
|
-
|
1.00
|
9/15/2016
|
|||||||||||
Accounting
Officer
|
19,167
|
-
|
-
|
1.47
|
2/13/2017
|
|||||||||||
25,000
|
25,000
|
-
|
1.49
|
3/15/2017
|
||||||||||||
Steven
C. Jones
|
-
|
-
|
-
|
NA
|
||||||||||||
Acting Principal
|
||||||||||||||||
Financial Officer
|
||||||||||||||||
and
Director
|
·
|
$20,000/year
|
·
|
Additional
$5,000/year for committee chairmen
|
·
|
$1,000
for each board meeting physically
attended
|
·
|
$500
for each board meeting attended via conference
call
|
Name
|
Fees
Earned
or Paid in
Cash
|
Stock
Awards
|
Warrant/
Option
Awards(1)
|
Non-Equity
Incentive Plan
Compensation
|
Change in
Pension Value
and
Nonqualified
Deferred
Compensation
Earnings
|
All Other
Compensation
|
Total
|
|||||||||||||||
Michael
T. Dent (2)
|
$
|
3,200
|
$
|
-
|
$
|
24,438
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
27,638
|
||||||||
Steven
Jones (2)
|
3,200
|
-
|
24,438
|
-
|
-
|
127,950
|
(4)
|
155,588
|
||||||||||||||
George
O'Leary (2)
|
2,600
|
-
|
52,563
|
(5)
|
-
|
-
|
9,500
|
64,663
|
||||||||||||||
Peter
Peterson (2)
|
1,400
|
-
|
24,438
|
-
|
-
|
-
|
25,838
|
|||||||||||||||
William
Robison (3)
|
2,000
|
-
|
11,688
|
-
|
-
|
-
|
13,688
|
|||||||||||||||
Marvin
Jaffe (3)
|
1,000
|
-
|
11,688
|
-
|
-
|
-
|
12,688
|
(1)
|
On
June 6, 2007, upon the conclusion of the private placement and sale of
2.67 million shares of our common stock at $1.50/share to disinterested
third parties, the board approved certain warrant compensation for each
director as an additional incentive to the nominal per meeting fees in
place. From the inception of the Company up until this time, no
stock-based compensation had ever been awarded to directors. All warrants
issued to directors had a strike price equal to the private placement
price per share ($1.50/share), a five year term and a three year vesting
period. For those directors who had been a director for at least two years
as of the date of the award, 25% of the warrants issued were deemed to
have vested upon issue. All of the remaining warrants were deemed to vest
ratably over a 36 month period. All of the warrants issued were valued
using the Black Scholes option/warrant valuation model with the following
assumptions: expected volatility – 35%, expected life – 4 years, risk-free
rate – 4.5%, and dividend yield – 0%. The Company is expensing the value
of these warrants over the vesting period pursuant to the methodology
outlined in SFAS 123(R). Pursuant to Regulation SK, Item 402, Paragraph
(k)(2)(iii), amounts indicated are the amounts expensed for such warrants
under SFAS 123 (R) for the year ended December 31,
2007.
|
(2) |
Awarded
100,000 warrants as Board Member
compensation
|
(3)
|
Awarded
75,000 warrants as Board Member
compensation
|
(4)
|
Other
compensation for Mr. Jones reflects his consulting compensation for
serving as our Acting Principle Financial
Officer.
|
(5)
|
In
addition to Mr. O’Leary’s Board compensation warrants, Mr. O’Leary was
also awarded 100,000 warrants on March 15, 2007 in connection with certain
consulting services performed on behalf of the Company. Such warrants have
a strike price of $1.49/share and a five year term. Half of such warrants
were deemed vested up front and the remaining half vest ratably over a 24
month period. Such warrants had a value of $36,000 using the Black Scholes
option/warrant valuation model.
|
Title of Class
|
Name And Address
Of Beneficial Owner
|
Amount
and Nature
Of
Beneficial
Ownership
|
Percent Of
Class(1)
|
|||||||
Common
|
Aspen
Select Healthcare, LP(2)
|
|
||||||||
1740
Persimmon Drive, Suite 100
|
||||||||||
Naples,
Florida 34109
|
11,815,220
|
33.6
|
%
|
|||||||
Common
|
Steven
C. Jones(3)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
13,055,386
|
36.7
|
%
|
|||||||
Common
|
Michael
T. Dent, M.D.(4)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
2,642,130
|
8.1
|
%
|
|||||||
Common
|
George
O’Leary(5)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
314,583
|
|
*
|
|||||||
Common
|
Robert
P. Gasparini(6)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, FL 33193
|
1,047,000
|
3.2
|
%
|
|||||||
Common
|
Peter
M. Peterson(7)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
11,926,862
|
33.8
|
%
|
|||||||
Common
|
William
J. Robison(8)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
111,380
|
|
*
|
|||||||
Common
|
Marvin
E. Jaffe, M.D.(9)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
63,096
|
|
*
|
Title of Class
|
Name And Address
Of Beneficial Owner
|
Amount
and Nature
Of
Beneficial
Ownership
|
Percent Of
Class(1)
|
|||||||
Common
|
Robert
J. Feeney(10)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
120,208
|
|
*
|
|||||||
Common
|
Matthew
W. Moore(11)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
51,875
|
|
*
|
|||||||
Common
|
Jerome
J. Dvonch(12)
|
|
||||||||
c/o
NeoGenomics, Inc.
|
||||||||||
12701
Commonwealth Blvd, Suite 5
|
||||||||||
Fort
Myers, Florida 33193
|
117,000
|
|
*
|
|||||||
Common
|
Directors
and Officers
as
a Group (10 persons)(13)
|
|
17,601,824
|
46.8
|
%
|
|||||
Common
|
SKL
Family Limited Partnership and
|
|||||||||
A.
Scott Logan Revocable Living Trust(14)
|
|
|||||||||
984
Oyster Court
|
||||||||||
Sanibel,
Florida 33957
|
3,533,750
|
10.7
|
%
|
|||||||
Common
|
1837
Partners, LP., 1837 Partners, QP,LP., and
|
|||||||||
1837
Partner Ltd. (RMB Capital)(15)
|
|
|||||||||
115
S. LaSalle, 34th floor
|
||||||||||
Chicago,
Illinois 60603
|
3,507,615
|
10.8
|
%
|
*
|
Less
than 1%
|
(1)
|
Beneficial
ownership is determined in accordance within the rules of the SEC and
generally includes voting and investment power with respect to securities.
Shares of common stock subject to securities exercisable or convertible
into shares of common stock that are currently exercisable or exercisable
within sixty days of December 31, 2008 are deemed to be beneficially owned
by the person holding such securities for the purpose of computing the
percentage of ownership of such persons, but are not treated as
outstanding for the purpose of computing the percentage ownership of any
other person. Percentage of ownership is based on
32,117,237 shares of common stock outstanding as of December 31,
2008.
|
(2)
|
Aspen
Select Healthcare, LP (“Aspen”) has
direct ownership of 6,238,279 shares and has certain warrants to purchase
3,050,000 shares, all of which are currently exercisable.
Aspen’s total also includes 2,526,941 shares to which Aspen has
received a voting proxy. The general partner of Aspen is
Medical Venture Partners, LLC, an entity controlled by Steven C. Jones and
Peter M. Peterson.
|
(3)
|
Steven
C. Jones, Acting Principal Financial Officer and director of the Company,
and his spouse have direct ownership of 724,826 shares. Mr.
Jones also has warrants exercisable within sixty days of December 31, 2008
to purchase an additional 93,965 shares. Totals for
Mr. Jones also include (i) 107,143 shares owned by Jones Network, LP, a
family limited partnership that Mr. Jones controls, (ii) 250,000 warrants
exercisable within sixty days of December 31, 2008 owned by Aspen Capital
Advisors, LLC, a company that Mr. Jones controls (iii) 32,475 warrants
exercisable within 60 days of December 31, 2008 owned by Gulf Pointe
Capital, LLC, a company that Mr. Jones and Mr. Peterson control, and (iv)
31,757 shares held in certain individual retirement and custodial
accounts. In addition, as a managing member of the
general partner of Aspen, he has the right to vote all shares controlled
by Aspen, thus all Aspen shares and currently exercisable warrants have
been added to his total (see Note
2).
|
(4)
|
Michael
T. Dent, M.D. is a director of the Company. Dr. Dent’s
beneficial ownership includes 900,000 shares held in a trust for the
benefit of Dr. Dent’s children (of which Dr. Dent and his attorney are the
sole trustees), warrants exercisable within sixty days of December 31,
2008 to purchase 139,659 shares and options exercisable within sixty days
of December 31, 2008 to purchase 400,000 shares. Dr. Dent’s
beneficial ownership also includes 1,202,471 shares owned directly by Dr.
Dent’s spouse.
|
(5)
|
George
O’Leary, a director of the Company, has direct ownership of warrants to
purchase 264,583 shares, which are exercisable within sixty days of
December 31, 2008. Mr. O’Leary also has options exercisable to
purchase 50,000 shares, which are exercisable within 60 days of December
31, 2008.
|
(6)
|
Robert
P. Gasparini, President of the Company, has direct ownership of 260,000
shares, and has options to purchase 787,000 shares, which are exercisable
within sixty days of December 31,
2008.
|
(7)
|
Peter
M. Peterson is a member of the Company’s board of directors and has direct
ownership of 12,500 shares and warrants exercisable within 60 days of
December 31, 2008 to purchase an additional 66,667 shares. In
addition, as a managing member of the general partner of Aspen, he has the
right to vote all shares controlled by Aspen, thus all Aspen shares and
currently exercisable warrants have been added to his total (see Note
2). Mr. Peterson’s beneficial ownership also includes 32,475
warrants exercisable within 60 days of December 31, 2008 owned by Gulf
Pointe Capital, LLC, a company that Mr. Jones and Mr. Peterson
control.
|
(8)
|
William
J. Robison, a director of the Company, has direct ownership of 58,713
shares and warrants to purchase 52,667 shares, which are exercisable
within 60 days of December 31,
2008.
|
(9)
|
Marvin
E. Jaffe, M.D., a director of the Company, has direct ownership of 21,429
shares and warrants to purchase 41,667 shares, which are exercisable
within 60 days of December 31,
2008.
|
(10)
|
Robert
J. Feeney, Vice President of Business Development, has direct ownership of
15,000 shares and options to purchase 105,208 shares, which are
exercisable within 60 days of December 31,
2008.
|
(11)
|
Matthew
W. Moore, Vice President of Research and Development, has options to
purchase 51,875 shares, which are exercisable within 60 days of December
31, 2008.
|
(12)
|
Jerome
J. Dvonch, Principal Accounting Officer, has options to purchase 117,000
shares, which are exercisable within 60 days of December 31,
2008.
|
(13)
|
The
total number of shares listed does not double count the shares that may be
beneficially attributable to more than one
person.
|
(14)
|
SKL
Family Limited Partnership has direct ownership of 2,000,000 shares and
warrants exercisable within 60 days of December 31, 2008 to purchase
900,000 shares. A. Scott Logan Living Revocable Trust has
direct ownership of 533,750 shares and warrants exercisable within 60 days
of December 31, 2008 to purchase 100,000 shares. A. Scott Logan
is the general partner of SKL Limited Family Partnership and trustee for
A. Scott Logan Living Revocable
Trust.
|
(15)
|
RMB
Capital and its affiliates have direct ownership of 3,172,615 shares and
warrants exercisable within 60 days of December 31, 2008 to purchase
320,000 shares. RMB Capital makes all the investment decisions
for the 1837 Partners LP., 1837 Partners QP, LP and 1837 Partners LTD who
own the vast majority shares of the shares listed. Amounts for
RMB capital also include 15,000 shares owned personally by its
members.
|
YEAR 2009
|
High Bid
|
Low Bid
|
|||||
1st
Quarter 2008 (through January 21, 2009)
|
$
|
0.74
|
$
|
0.56
|
YEAR 2008
|
High Bid
|
Low Bid
|
|||||
4th
Quarter 2008
|
$
|
1.05
|
$
|
0.56
|
|||
3rd
Quarter 2008
|
$
|
1.15
|
$
|
0.83
|
|||
2nd
Quarter 2008
|
$
|
1.35
|
$
|
0.86
|
|||
1st
Quarter 2008
|
$
|
1.12
|
$
|
0.77
|
YEAR 2007
|
High Bid
|
Low Bid
|
|||||
4th
Quarter 2007
|
$
|
1.59
|
$
|
1.02
|
|||
3rd
Quarter 2007
|
$
|
1.70
|
$
|
1.05
|
|||
2nd
Quarter 2007
|
$
|
1.90
|
$
|
1.41
|
|||
1st
Quarter 2007
|
$
|
1.79
|
$
|
1.39
|
·
|
By
the stockholders;
|
·
|
By
our Board of Directors by majority vote of a quorum consisting of
directors who were not parties to that act, suit or
proceeding;
|
·
|
If
a majority vote of a quorum consisting of directors who were not parties
to the act, suit or proceeding cannot be obtained, by independent legal
counsel in a written opinion; or
|
·
|
If
a quorum consisting of directors who were not parties to the act, suit or
proceeding cannot be obtained, by independent legal counsel in a written
opinion;
|
·
|
Expenses
of officers and directors incurred in defending a civil or criminal
action, suit or proceeding must be paid by us as they are incurred and in
advance of the final disposition of the action, suit or proceeding, upon
receipt of an undertaking by the director or officer to repay the amount
if it is ultimately determined by a court of competent jurisdiction that
he is not entitled to be indemnified by
us.
|
·
|
To
the extent that a director, officer, employee or agent has been successful
on the merits or otherwise in defense of any action, suit or proceeding
referred to in subsections 1 and 2, or in defense of any claim, issue or
matter therein, we shall indemnify him against expenses, including
attorneys’ fees, actually and reasonably incurred by him in connection
with the defense.
|
|
PAGE
|
|
CONSOLIDATED FINANCIAL
STATEMENTS—SEPTEMBER 30, 2008 (unaudited)
|
||
Condensed
Consolidated Balance Sheets as of September 30, 2008 and
December 31, 2007
|
F-1
|
|
Condensed
Consolidated Statements of Operations for the Three and Nine Months Ended
September 30, 2008 and 2007
|
F-2
|
|
Condensed
Consolidated Statements of Cash Flows for the Nine Months Ended September
30, 2008 and 2007
|
F-3
|
|
Notes
to Unaudited Condensed Consolidated Financial Statements as of September
30, 2008
|
F -4
|
|
PAGE
|
|
CONSOLIDATED FINANCIAL
STATEMENTS—DECEMBER 31, 2007 and
2006
|
||
Report
of Independent Registered Public Accounting Firm
|
F-10
|
|
Consolidated
Balance Sheets as of December 31, 2007 and
2006
|
F-11
|
|
Consolidated
Statements of Operations for the Years Ended December 31, 2007 and
2006
|
F-12
|
|
Consolidated
Statements of Stockholders’ Equity for the Years Ended December 31, 2007
and 2006
|
F-13
|
|
Consolidated
Statements of Cash Flows for the Years Ended December 31, 2007 and
2006
|
F-14
|
|
Notes
to Consolidated Financial Statements as of and for the years ended
December 31, 2007 and 2006
|
F-15
|
September 30,
2008
|
December 31,
2007
|
||||||
ASSETS
|
|||||||
CURRENT
ASSETS
|
|||||||
Cash
and cash equivalents
|
$
|
631,365
|
$
|
210,573
|
|||
Accounts
receivable (net of allowance for doubtful accounts of $283,111 and
$414,548, respectively)
|
3,381,066
|
3,236,751
|
|||||
Inventories
|
344,608
|
304,750
|
|||||
Other
current assets
|
900,146
|
400,168
|
|||||
Total
current assets
|
5,257,185
|
4,152,242
|
|||||
PROPERTY AND
EQUIPMENT
(net of accumulated depreciation of $1,374,942 and
$862,030,respectively)
|
2,495,146
|
2,108,083
|
|||||
OTHER ASSETS
|
275,087
|
260,575
|
|||||
TOTAL
ASSETS
|
$
|
8,027,418
|
$
|
6,520,900
|
|||
LIABILITIES AND
STOCKHOLDERS’ EQUITY
|
|||||||
CURRENT
LIABILITIES
|
|||||||
Accounts
payable
|
$
|
1,904,694
|
$
|
1,799,159
|
|||
Accrued
expenses and other liabilities
|
955,405
|
1,319,580
|
|||||
Due
to affiliates (net of discount of $39,285)
|
- | - | |||||
Revolving
credit line
|
1,176,221
|
-
|
|||||
Short-term
portion of equipment capital leases
|
449,776
|
242,966
|
|||||
Total
current liabilities
|
4,486,096
|
3,361,705
|
|||||
LONG TERM LIABILITIES
|
|||||||
Long-term
portion of equipment capital leases
|
1,054,321
|
837,081
|
|||||
TOTAL
LIABILITIES
|
5,540,417
|
4,198,786
|
|||||
STOCKHOLDERS’
EQUITY
|
|||||||
Common
stock, $.001 par value, (100,000,000 shares authorized; 31,686,355 and
31,391,660 shares issued and outstanding,
respectively)
|
31,686
|
31,391
|
|||||
Additional
paid-in capital
|
17,373,756
|
16,820,954
|
|||||
Deferred
stock compensation
|
- | - | |||||
Accumulated
deficit
|
(14,918,441
|
)
|
(14,530,231
|
)
|
|||
Total
stockholders’ equity
|
2,487,001
|
2,322,114
|
|||||
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY
|
$
|
8,027,418
|
$
|
6,520,900
|
For the
Nine-
Months
Ended
September
30, 2008
|
For the
Nine-
Months
Ended
September
30, 2007
|
For the
Three-
Months
Ended
September
30, 2008
|
For the
Three-
Months
Ended
September
30, 2007
|
||||||||||
NET
REVENUE
|
$
|
14,094,959
|
$
|
7,709,408
|
$
|
5,050,796
|
$
|
3,122,714
|
|||||
COST OF
REVENUE
|
6,577,549
|
3,623,860
|
2,535,318
|
1,521,313
|
|||||||||
GROSS PROFIT
|
7,517,410
|
4,085,548
|
2,515,478
|
1,601,401
|
|||||||||
OPERATING
EXPENSES
|
|||||||||||||
General
and administrative
|
7,706,284
|
5,664,053
|
2,635,608
|
2,178,339
|
|||||||||
Interest
expense, net
|
199,336
|
205,806
|
74,995
|
14,325
|
|||||||||
Total
operating expenses
|
7,905,620
|
5,869,859
|
2,710,603
|
2,192,664
|
|||||||||
NET INCOME (LOSS)
|
$
|
(388,210
|
)
|
$
|
(1,784,311
|
)
|
$
|
(195,125
|
)
|
$
|
(591,263
|
)
|
|
NET INCOME (LOSS) PER SHARE | |||||||||||||
-
Basic
|
$
|
(0.01
|
)
|
$
|
(0.06
|
)
|
$
|
(0.01
|
)
|
$
|
(0.02
|
)
|
|
-
Diluted
|
$
|
(0.01
|
)
|
$
|
(0.06
|
)
|
$
|
(0.01
|
)
|
$
|
(0.02
|
)
|
|
WEIGHTED AVERAGE NUMBER
OF SHARES
OUTSTANDING
|
|||||||||||||
-
Basic
|
31,414,065
|
29,221,778
|
31,440,327
|
31,309,353
|
|||||||||
-
Diluted
|
31,414,065
|
29,221,778
|
31,440,327
|
31,309,353
|
September 30, 2008
|
September 30, 2007
|
||||||
CASH FLOWS FROM OPERATING
ACTIVITIES
|
|||||||
Net
Loss
|
$
|
(388,210
|
)
|
$
|
(1,784,311
|
)
|
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|||||||
Provision
for bad debts
|
1,095,387
|
506,286
|
|||||
Depreciation
|
512,913
|
295,297
|
|||||
Impairment
of assets
|
-
|
2,235
|
|||||
Amortization
of debt issue costs
|
35,321
|
15,615
|
|||||
Amortization
of lease cap costs
|
4,080
|
2,516
|
|||||
Amortization
of relocation costs
|
8,862
|
15,450
|
|||||
Amortization
of credit facility warrants
|
-
|
39,285
|
|||||
Stock-based
compensation
|
229,539
|
203,850
|
|||||
Non-cash
consulting expenses
|
99,813
|
121,879
|
|||||
Changes
in assets and liabilities, net:
|
|||||||
(Increase)
decrease in accounts receivable, net of write-offs
|
(1,239,702
|
)
|
(1,765,635
|
)
|
|||
(Increase)
decrease in inventories
|
(39,857
|
)
|
(299,269
|
)
|
|||
(Increase)
decrease in pre-paid expenses
|
(405,841
|
)
|
(191,434
|
)
|
|||
(Increase)
decrease in deposits
|
(14,512
|
)
|
(16,925
|
)
|
|||
Increase
(decrease) in accounts payable and other liabilities
|
(79,447
|
)
|
665,998
|
||||
NET CASH USED IN OPERATING
ACTIVITIES
|
(181,654
|
)
|
(2,189,163
|
)
|
|||
CASH FLOWS FROM INVESTING
ACTIVITIES
|
|||||||
Purchases
of property and equipment
|
(370,218
|
)
|
(406,747
|
)
|
|||
Purchase
of convertible debenture
|
-
|
(200,000
|
)
|
||||
NET CASH USED IN INVESTING
ACTIVITIES
|
(370,218
|
)
|
(606,747
|
)
|
|||
CASH FLOWS FROM FINANCING
ACTIVITIES
|
|||||||
Advances
/ (repayments) to affiliates, net
|
-
|
(1,675,000
|
)
|
||||
Advances
/ (repayments) on credit facility
|
1,176,221
|
-
|
|||||
Repayment
of capital leases
|
(244,612
|
)
|
(110,000
|
)
|
|||
Issuance
of common stock and warrants for cash, net of transaction
expenses
|
41,055
|
5,266,578
|
|||||
Repayment
of notes payable
|
-
|
(2,000
|
)
|
||||
NET CASH PROVIDED BY FINANCING
ACTIVITIES
|
972,664
|
3,479,578
|
|||||
NET INCREASE IN CASH AND CASH
EQUIVALENTS
|
420,792
|
683,668
|
|||||
CASH AND CASH EQUIVALENTS,
BEGINNING OF PERIOD
|
210,573
|
126,266
|
|||||
CASH AND CASH EQUIVALENTS, END
OF PERIOD
|
$
|
631,365
|
$
|
809,934
|
|||
SUPPLEMENTAL DISCLOSURE OF CASH
FLOW INFORMATION
|
|||||||
Interest
paid
|
$
|
171,606
|
$
|
169,320
|
|||
Income
taxes paid
|
$
|
-
|
$
|
-
|
|||
NON-CASH INVESTING AND
FINANCING ACTIVITIES
|
|||||||
Equipment
leased under capital leases, including $140,000 in accrued expenses at
December 31, 2007
|
$
|
538,761
|
$
|
464,811
|
|||
Equipment
purchased and included in accounts payable at September 30,
2008
|
$
|
126,227
|
$
|
-
|
d) |
Purchase
not less than all of the equipment for its then Fair Market Value (“FMV”)
not to exceed 15% of the original equipment
cost.
|
e) |
Extend
the lease term for a minimum of six (6)
months.
|
f) |
Return
not less than all the equipment at conclusion of the lease
term.
|
(d) |
Renew
the lease with respect to such equipment for an additional 12 months at
fair market value;
|
(e) |
Purchase
the equipment at fair market value, which price will not be less than 10%
of cost nor more than 14% of cost;
|
(f) |
Extend
the term for an additional six months at 35% of the monthly rent paid by
lessee during the initial term, equipment may then be purchased for the
lesser of fair market value or 8% of cost;
or
|
(b) |
Return
the equipment subject to a remarketing charge equal to 6% of
cost.
|
2007
|
2006
|
|||||||
ASSETS
|
||||||||
CURRENT
ASSETS
|
||||||||
Cash
and cash equivalents
|
$ | 210,573 | $ | 126,266 | ||||
Accounts
receivable (net of allowance for doubtful accounts of $414,548 and
$103,463, respectively)
|
3,236,751 | 1,549,758 | ||||||
Inventories
|
304,750 | 117,362 | ||||||
Other
current assets
|
400,168 | 102,172 | ||||||
Total
current assets
|
4,152,242 | 1,895,558 | ||||||
PROPERTY AND EQUIPMENT
(net of accumulated depreciation of $862,030 and $494,942,
respectively)
|
2,108,083 | 1,202,487 | ||||||
OTHER
ASSETS
|
260,575 | 33,903 | ||||||
TOTAL
ASSETS
|
$ | 6,520,900 | $ | 3,131,948 | ||||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
||||||||
CURRENT
LIABILITIES
|
||||||||
Accounts
payable
|
$ | 1,799,159 | $ | 697,754 | ||||
Accrued
compensation
|
370,496 | 133,490 | ||||||
Accrued
expenses and other liabilities
|
574,084 | 67,098 | ||||||
Due
to affiliates (net of discount of $39,285)
|
- | 1,635,715 | ||||||
Legal
contingency (Note G)
|
375,000 | - | ||||||
Short-term
portion of equipment capital leases
|
242,966 | 94,430 | ||||||
Total
current liabilities
|
3,361,705 | 2,628,487 | ||||||
LONG
TERM LIABILITIES
|
||||||||
Long-term
portion of equipment capital leases
|
837,081 | 448,947 | ||||||
TOTAL
LIABILITIES
|
$ | 4,198,786 | $ | 3,077,434 | ||||
Commitments
and contingencies
|
||||||||
STOCKHOLDERS’
EQUITY
|
||||||||
Common
stock, $.001 par value, (100,000,000 shares authorized; 31,391,660 and
27,061,476 shares issued and outstanding,
respectively)
|
31,391 | 27,061 | ||||||
Additional
paid-in capital
|
16,820,954 | 11,177,512 | ||||||
Accumulated
deficit
|
(14,530,231 | ) | (11,150,059 | ) | ||||
Total
stockholders’ equity
|
2,322,114 | 54,514 | ||||||
TOTAL
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$ | 6,520,900 | $ | 3,131,948 |
|
2007
|
2006
|
|||||
|
|||||||
NET
REVENUE
|
$
|
11,504,725
|
$
|
6,475,996
|
|||
COST OF
REVENUE
|
5,522,775
|
2,759,190
|
|||||
GROSS
MARGIN
|
$
|
5,981,950
|
$
|
3,716,806
|
|||
OTHER OPERATING
EXPENSE
|
|||||||
General
and administrative
|
$
|
9,122,922
|
$
|
3,576,812
|
|||
|
|||||||
INCOME / (LOSS) FROM
OPERATIONS
|
$
|
(3,140,972
|
)
|
$
|
139,994
|
||
|
|||||||
OTHER INCOME /
(EXPENSE):
|
|||||||
Other
income
|
$
|
24,256
|
$
|
55,970
|
|||
Interest
expense
|
(263,456
|
)
|
(325,625
|
)
|
|||
Other
income / (expense) – net
|
$
|
(239,200
|
)
|
$
|
(269,655
|
)
|
|
NET LOSS
|
(3,380,172
|
)
|
(129,661
|
)
|
|||
NET LOSS PER
SHARE -
Basic and Diluted
|
$
|
(0.11
|
)
|
$
|
(0.00
|
)
|
|
WEIGHTED AVERAGE
NUMBER
OF SHARES OUTSTANDING
– Basic
and Diluted
|
29,764,289
|
26,166,031
|
|
Common
|
Common
|
Additional
|
Deferred
|
|
|
|||||||||||||
|
Stock
|
Stock
|
Paid-In
|
Stock
|
Accumulated
|
|
|||||||||||||
|
Shares
|
Amount
|
Capital
|
Compensation
|
Deficit
|
Total
|
|||||||||||||
|
|||||||||||||||||||
Balances, December 31,
2005
|
22,836,754
|
$
|
22,836
|
$
|
10,005,308
|
$
|
(2,685
|
)
|
$
|
(11,020,398
|
)
|
$
|
(994,939
|
)
|
|||||
|
|||||||||||||||||||
Common
stock issuances for cash
|
3,530,819
|
3,531
|
1,099,469
|
-
|
-
|
1,103,000
|
|||||||||||||
Common
stock issued for acquisition
|
100,000
|
100
|
49,900
|
-
|
-
|
50,000
|
|||||||||||||
Transaction
fees and expenses
|
-
|
-
|
(80,189
|
)
|
-
|
-
|
(80,189
|
)
|
|||||||||||
Adjustment
of credit facility discount
|
-
|
-
|
2,365
|
-
|
-
|
2,365
|
|||||||||||||
Exercise
of stock options and warrants
|
546,113
|
546
|
66,345
|
-
|
-
|
66,891
|
|||||||||||||
Warrants
and stock issued for services
|
7,618
|
8
|
7,642
|
-
|
-
|
7,650
|
|||||||||||||
Payment
of note on Yorkville Capital fee
|
-
|
-
|
(50,000
|
)
|
-
|
-
|
(50,000
|
)
|
|||||||||||
Stock
issued to settle accounts payable
|
40,172
|
40
|
15,627
|
-
|
-
|
15,667
|
|||||||||||||
Stock
compensation expense
|
-
|
-
|
63,730
|
-
|
-
|
63,730
|
|||||||||||||
Reclassification
of deferred compensation to additional paid in capital upon adoption of
SFAS 123R
|
-
|
-
|
(2,685
|
)
|
2,685
|
-
|
-
|
||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
(129,661
|
)
|
(129,661
|
)
|
|||||||||||
Balances, December 31,
2006
|
27,061,476
|
$
|
27,061
|
$
|
11,177,512
|
-
|
$
|
(11,150,059
|
)
|
$
|
54,514
|
||||||||
|
|||||||||||||||||||
Common
stock issuances for cash
|
4,154,684
|
4,155
|
5,574,682
|
-
|
-
|
5,578,837
|
|||||||||||||
Transaction
fees and expenses
|
-
|
-
|
(346,110
|
)
|
-
|
-
|
(346,110
|
)
|
|||||||||||
Exercise
of stock options and warrants
|
175,500
|
175
|
53,619
|
-
|
-
|
53,794
|
|||||||||||||
Warrants
issued for services
|
-
|
-
|
159,153
|
-
|
-
|
159,153
|
|||||||||||||
Stock
compensation expense
|
-
|
-
|
202,098
|
-
|
-
|
202,098
|
|||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
(3,380,172
|
)
|
(3,380,172
|
)
|
|||||||||||
Balances, December 31,
2007
|
31,391,660
|
$
|
31,391
|
$
|
16,820,954
|
$
|
-
|
$
|
(14,530,231
|
)
|
$
|
2,322,114
|
|
2007
|
2006
|
|||||
CASH FLOWS FROM OPERATING
ACTIVITIES
|
|||||||
Net
Loss
|
$
|
(3,380,172
|
)
|
$
|
(129,661
|
)
|
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|||||||
Depreciation
and amortization
|
451,459
|
233,632
|
|||||
Impairment
of assets
|
2,235
|
53,524
|
|||||
Amortization
of credit facility warrants and debt issue costs
|
54,900
|
72,956
|
|||||
Stock
based compensation
|
202,098
|
63,730
|
|||||
Non-cash
consulting
|
159,153
|
7,650
|
|||||
Other
non-cash expenses
|
29,423
|
59,804
|
|||||
Provision
for bad debts
|
1,013,804
|
444,133
|
|||||
Changes
in assets and liabilities, net:
|
|||||||
(Increase)
decrease in accounts receivable, net of write-offs
|
(2,700,797
|
)
|
(1,442,791
|
)
|
|||
(Increase)
decrease in inventory
|
(187,388
|
)
|
(57,362
|
)
|
|||
(Increase)
decrease in prepaid expenses
|
(343,032
|
)
|
(101,805
|
)
|
|||
(Increase)
decrease in other current assets
|
(26,671
|
)
|
(31,522
|
)
|
|||
Increase
(decrease) in deferred revenues
|
-
|
(100,000
|
)
|
||||
Increase
(decrease) in legal contingency
|
375,000
|
-
|
|||||
Increase
(decrease) in accounts payable and other liabilities
|
1,707,397
|
233,930
|
|||||
NET CASH USED IN OPERATING
ACTIVITIES
|
(2,642,591
|
)
|
(693,782
|
)
|
|||
|
|||||||
CASH FLOWS FROM INVESTING
ACTIVITIES
|
|||||||
Purchases
of property and equipment
|
(516,144
|
)
|
(398,618
|
)
|
|||
Investment
in other assets (Power 3)
|
(200,000
|
)
|
-
|
||||
NET CASH USED IN INVESTING
ACTIVITIES
|
(716,144
|
)
|
(398,618
|
)
|
|||
|
|||||||
CASH FLOWS FROM FINANCING
ACTIVITIES
|
|||||||
Advances
(repayments) from/to affiliates, net
|
(1,675,000
|
)
|
175,000
|
||||
Notes
payable
|
(2,000
|
)
|
2,000
|
||||
Repayment
of capital lease obligations
|
(166,479
|
)
|
(58,980
|
)
|
|||
Issuance
of common stock and warrants for cash , net of transaction
expenses
|
5,286,521
|
1,089,702
|
|||||
NET CASH PROVIDED BY FINANCING
ACTIVITIES
|
3,443,042
|
1,207,722
|
|||||
|
|||||||
NET CHANGE IN CASH AND CASH
EQUIVALENTS
|
84,307
|
115,322
|
|||||
|
|||||||
CASH AND CASH EQUIVALENTS,
BEGINNING OF YEAR
|
126,266
|
10,944
|
|||||
|
|||||||
CASH AND CASH EQUIVALENTS, END
OF YEAR
|
$
|
210,573
|
$
|
126,266
|
|||
|
|||||||
SUPPLEMENTAL DISCLOSURE OF CASH
FLOW INFORMATION
|
|||||||
Interest
paid
|
$
|
204,670
|
$
|
269,316
|
|||
Equipment
leased under capital leases
|
$
|
703,145
|
$
|
602,357
|
|||
Income
taxes paid
|
$
|
-
|
$
|
-
|
|||
Common
stock issued for acquisition
|
$
|
-
|
$
|
50,000
|
|||
Common
stock issued in settlement of financing fees
|
$
|
-
|
$
|
50,000
|
|
2007
|
2006
|
Estimated
Useful
Lives in
Years
|
|||||||||
Equipment
|
$ | 2,319,601 | $ | 1,566,330 | 3-7 | |||||||
Leasehold
Improvements
|
51,989 | 12,945 | 3-5 | |||||||||
Furniture
& Fixtures
|
163,324 | 118,154 | 7 | |||||||||
Computer
Hardware
|
152,405 | - | 3 | |||||||||
Computer
Software
|
209,134 | - | 3 | |||||||||
Assets
not yet placed in service
|
73,660 | - | - | |||||||||
Subtotal
|
2,970,113 | 1,697,429 | ||||||||||
Less
accumulated depreciation and amortization
|
(862,030 | ) | (494,942 | ) | ||||||||
Furniture
and Equipment, net
|
$ | 2,108,083 | $ | 1,202,487 |
2007
|
2006
|
|||||||
Equipment
|
$ | 1,127,889 | $ | 585,131 | ||||
Furniture
& Fixtures
|
22,076 | 17,226 | ||||||
Computer
Hardware
|
49,086 | - | ||||||
Computer
Software
|
94,963 | - | ||||||
Subtotal
|
1,294,014 | 602,357 | ||||||
Less
accumulated depreciation and amortization
|
(248,711 | ) | (43,772 | ) | ||||
Property
and Equipment under capital leases, net
|
$ | 1,045,303 | $ | 558,585 |
Net
current deferred income tax asset:
|
||||
|
||||
Allowance
for doubtful accounts
|
$
|
159,900
|
||
Less
valuation allowance
|
(159,900
|
)
|
||
Total
|
$
|
-
|
Net
non-current deferred income tax asset:
|
||||
|
||||
Net
operating loss carryforwards
|
$
|
1,830,450
|
||
Accumulated
depreciation and impairment
|
(166,000
|
)
|
||
Subtotal
|
1,664,450
|
|||
Less
valuation allowance
|
(1,664,450
|
)
|
||
Total
|
$
|
-
|
Net
current deferred income tax asset:
|
||||
Allowance
for doubtful accounts
|
$ | 39,900 | ||
Less
valuation allowance
|
(39,900 | ) | ||
Total
|
$ | - |
Net
non-current deferred income tax asset:
|
||||
Net
operating loss carryforwards
|
$ | 816,500 | ||
Accumulated
depreciation and impairment
|
(75,600 | ) | ||
Subtotal
|
740,900 | |||
Less
valuation allowance
|
(740,900 | ) | ||
Total
|
$ | - |
2007
|
2006
|
||||||
Expected
term (in years)
|
4.7
|
5.4
|
|||||
Risk-free
interest rate (%)
|
4.6
|
%
|
4.8
|
%
|
|||
Expected
volatility (%)
|
35
|
%
|
36
|
%
|
|||
Dividend
yield (%)
|
0
|
%
|
0
|
%
|
|||
Weighted
average fair value/share at grant date
|
$
|
0.45
|
$
|
0.23
|
|
Number
of
Shares |
Weighted
Average |
|||||
|
|
Exercise
Price |
|||||
Outstanding
at December 31, 2005
|
1,735,000
|
$
|
0.27
|
||||
|
|||||||
Granted
|
1,011,897
|
0.68
|
|||||
Exercised
|
(211,814
|
)
|
0.30
|
||||
Canceled
|
(428,083
|
)
|
0.42
|
||||
Outstanding
at December 31, 2006
|
2,107,000
|
0.43
|
|||||
|
|||||||
Granted
|
1,232,583
|
1.48
|
|||||
Exercised
|
(175,500
|
)
|
0.31
|
||||
Canceled
|
(368,039
|
)
|
1.14
|
||||
Outstanding
at December 31, 2007
|
2,796,044
|
0.81
|
|||||
Exercisable
at December 31, 2007
|
1,721,874
|
$
|
0.55
|
Options Outstanding Expected to Vest
|
|||||||||||||||||||
Range of
Exercise prices(s) |
Number
Outstanding |
Weighted
Average Remaining Contractual Life (yrs) |
Weighted
Average Exercise Price |
Number
Exercisable |
Options
Exercisable
Weighted
Average
Remaining
Contractual Life(Yrs)
|
Weighted
Average Exercise price |
|||||||||||||
|
1,120,000
|
6.6
|
$
|
0.25
|
1,120,000
|
6.6
|
$
|
0.25
|
|||||||||||
0.31-0.46
|
94,750
|
7.4
|
0.35
|
68,750
|
7.4
|
0.35
|
|||||||||||||
0.47-0.71
|
389,000
|
8.4
|
0.62
|
159,666
|
8.2
|
0.62
|
|||||||||||||
0.72-1.08
|
60,000
|
8.7
|
1.00
|
20,001
|
8.7
|
1.00
|
|||||||||||||
1.09-1.47
|
608,042
|
7.0
|
1.39
|
256,042
|
9.0
|
1.45
|
|||||||||||||
1.48-1.82
|
524,252
|
8.6
|
1.55
|
97,415
|
8.7
|
1.54
|
|||||||||||||
|
2,796,044
|
7.4
|
$
|
0.81
|
1,721,874
|
7.3
|
$
|
0.55
|
Years
ending December 31,
|
||||
2008
|
$
|
714,735
|
||
2009
|
732,724
|
|||
2010
|
654,430
|
|||
2011
|
325,618
|
|||
2012
|
57,140
|
|||
Total
minimum lease payments
|
$
|
2,484,647
|
Years
ending December 31,
|
||||
2008
|
$
|
373,344
|
||
2009
|
373,344
|
|||
2010
|
344,728
|
|||
2011
|
211,276
|
|||
2012
|
78,507
|
|||
Total
future minimum lease payments
|
1,381,199
|
|||
Less
amount representing interest
|
(301,152
|
)
|
||
Present
value of future minimum lease payments
|
1,080,047
|
|||
Less
current maturities
|
(242,966
|
)
|
||
Obligations
under capital leases – long term
|
$
|
837,081
|
Strike
price
|
$
|
0.50
|
Market
price
|
$
|
0.35
|
|||||
Term
|
5
years
|
Volatility
|
22.7
|
%
|
||||||
Risk-free
rate
|
4.50
|
%
|
Dividend
yield
|
0
|
%
|
|||||
Warrant
value
|
$
|
0.0525347
|
Number
of warrants
|
$
|
2,500
|
|||||
Total
value
|
$
|
131,337
|
Request
Date
|
Completion Date
|
Shares of
Common Stock |
Gross
Proceeds |
Yorkville
Fee |
Escrow Fee
|
Net
Proceeds |
ASP(1)
|
|||||||||||||||
8/29/2005
|
9/8/2005
|
63,776
|
$
|
25,000
|
$
|
1,250
|
$
|
500
|
$
|
23,250
|
||||||||||||
12/10/2005
|
12/18/2005
|
241,779
|
50,000
|
2,500
|
500
|
47,000
|
||||||||||||||||
Subtotal –
2005
|
305,555
|
$
|
75,000
|
$
|
3,750
|
$
|
1,000
|
$
|
70,250
|
$
|
0.25
|
|||||||||||
7/19/2006
|
7/28/2006
|
83,491
|
53,000
|
2,500
|
500
|
50,000
|
||||||||||||||||
8/8/2006
|
8/16/2006
|
279,486
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
10/18/2006
|
10/23/2006
|
167,842
|
200,000
|
10,000
|
500
|
189,500
|
||||||||||||||||
Subtotal –
2006
|
530,819
|
$
|
503,000
|
$
|
25,000
|
$
|
1,500
|
$
|
476,500
|
$
|
0.95
|
|||||||||||
12/29/2006
|
1/10/2007
|
98,522
|
150,000
|
7,500
|
500
|
142,000
|
||||||||||||||||
1/16/2007
|
1/24/2007
|
100,053
|
150,000
|
7,500
|
500
|
142,000
|
||||||||||||||||
2/1/2007
|
2/12/2007
|
65,902
|
100,000
|
5,000
|
500
|
94,500
|
||||||||||||||||
2/19/2007
|
2/28/2007
|
166,611
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
2/28/2007
|
3/7/2007
|
180,963
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
4/5/2007
|
4/16/2007
|
164,777
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
4/20/2007
|
4/30/2007
|
173,467
|
250,000
|
12,500
|
500
|
237,000
|
||||||||||||||||
Subtotal –
2007
|
950,295
|
$
|
1,400,000
|
$
|
70,000
|
$
|
3,500
|
$
|
1,326,500
|
$
|
1.48
|
|||||||||||
Total Since
Inception
|
1,786,
669
|
$
|
1,978,000
|
$
|
98,750
|
$
|
6,000
|
$
|
1,873,250
|
$
|
1.19
|
Securities
and Exchange Commission Registration Fee
|
$
|
179
|
||
Printing
and Engraving Expenses
|
$
|
1,000
|
||
Accounting
Fees and Expenses
|
$
|
10,000
|
||
Legal
Fees and Expenses
|
$
|
50,000
|
||
Miscellaneous
|
$
|
3,821
|
||
TOTAL
|
$
|
65,000
|
·
|
By
the stockholders;
|
·
|
By
our Board of Directors by majority vote of a quorum consisting of
directors who were not parties to that act, suit or
proceeding;
|
·
|
If
a majority vote of a quorum consisting of directors who were not parties
to the act, suit or proceeding cannot be obtained, by independent legal
counsel in a written opinion; or
|
·
|
If
a quorum consisting of directors who were not parties to the act, suit or
proceeding cannot be obtained, by independent legal counsel in a written
opinion;
|
·
|
Expenses
of officers and directors incurred in defending a civil or criminal
action, suit or proceeding must be paid by us as they are incurred and in
advance of the final disposition of the action, suit or proceeding, upon
receipt of an undertaking by the director or officer to repay the amount
if it is ultimately determined by a court of competent jurisdiction that
he is not entitled to be indemnified by
us.
|
·
|
To
the extent that a director, officer, employee or agent has been successful
on the merits or otherwise in defense of any action, suit or proceeding
referred to in subsections 1 and 2, or in defense of any claim, issue or
matter therein, we shall indemnify him against expenses, including
attorneys’ fees, actually and reasonably incurred by him in connection
with the defense.
|
Exhibit No.
|
Description of Exhibit
|
Location
|
||
3.1
|
Articles
of Incorporation, as amended
|
Incorporated
by reference to the Company’s Registration Statement on Form SB-2 as filed
with the SEC on February 10, 1999
|
||
3.2
|
Amendment
to Articles of Incorporation filed with the Nevada Secretary of State on
January 3, 2002
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on May 20, 2003
|
||
3.3
|
Amendment
to Articles of Incorporation filed with the Nevada Secretary of State on
April 11, 2003
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on May 20, 2003
|
||
3.4
|
Amended
and Restated Bylaws, dated October 14, 2003
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-QSB as filed
with the SEC on November 14, 2003
|
||
3.5
|
NeoGenomics,
Inc. 2003 Equity Incentive Plan
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-QSB as filed
with the United States SEC on November 14, 2003
|
||
3.6
|
Amended
and Restated NeoGenomics Equity Incentive Plan, dated October 31,
2006
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-QSB for the
quarter ended September 30, 2006, as filed with the SEC on November 17,
2006
|
||
5.1
|
Opinion
of Counsel
|
Provided
herewith.
|
||
10.1
|
Loan
Agreement between NeoGenomics, Inc. and Aspen Select Healthcare, L.P.
dated March 23, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on March 30, 2005
|
||
10.2
|
Amended
and Restated Registration Rights Agreement between NeoGenomics, Inc. and
Aspen Select Healthcare, L.P. and individuals dated March 23,
2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on March 30, 2005
|
||
10.3
|
Guaranty
of NeoGenomics, Inc., dated March 23, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on March 30, 2005
|
||
10.4
|
Stock
Pledge Agreement between NeoGenomics, Inc. and Aspen Select Healthcare,
L.P., dated March 23, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on March 30, 2005
|
||
10.5
|
Warrants
issued to Aspen Select Healthcare, L.P., dated March 23,
2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on March 30, 2005
|
||
10.6
|
Security
Agreement between NeoGenomics, Inc. and Aspen Select Healthcare, L.P.,
dated March 23, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on March 30, 2005
|
Exhibit No.
|
Description of Exhibit
|
Location
|
||
10.7
|
Amended
and Restated Shareholders’ Agreement dated March 23, 2005 among
Neogenomics, Inc., a Nevada corporation, Michael Dent, Aspen Select
Healthcare, LP, John Elliot, Steven Jones and Larry
Kuhnert
|
Incorporated by reference to the
Company’s Registration Statement on Form S-1 as filed with
the SEC on November 28,
2008
|
||
10.8
|
Standby
Equity Distribution Agreement with Cornell Capital Partners, L.P. dated
June 6, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on June 8, 2005
|
||
10.9
|
Registration
Rights Agreement with Cornell Capital Partners, L.P. related to the
Standby Equity Distribution dated June 6, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on June 8, 2005
|
||
10.10
|
Placement
Agent Agreement with Spartan Securities Group, Ltd., related to the
Standby Equity Distribution dated June 6, 2005
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on June 8, 2005
|
||
10.11
|
Amended
and Restated Loan Agreement between NeoGenomics, Inc. and Aspen Select
Healthcare, L.P., dated March 30, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.12
|
Amended
and Restated Warrant Agreement between NeoGenomics, Inc. and Aspen Select
Healthcare, L.P., dated January 21, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.13
|
Amended
and Restated Security Agreement between NeoGenomics, Inc. and Aspen Select
Healthcare, L.P., dated March 30, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.14
|
Registration
Rights Agreement between NeoGenomics, Inc. and Aspen Select Healthcare,
L.P., dated March 30, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.15
|
Warrant
Agreement between NeoGenomics, Inc. and SKL Family Limited Partnership,
L.P. issued January 23, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.16
|
Warrant
Agreement between NeoGenomics, Inc. and Aspen Select Healthcare, L.P.
issued March 14, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.17
|
Warrant
Agreement between NeoGenomics, Inc. and Aspen Select Healthcare, L.P.
issued March 30, 2006
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 1, 2006
|
||
10.18
|
Agreement
with Power3 Medical Products, Inc. regarding the Formation of Joint
Venture & Issuance of Convertible Debenture and Related
Securities
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB, as filed with
the SEC on April 2, 2007
|
Exhibit No.
|
Description of Exhibit
|
Location
|
||
10.19
|
Securities
Purchase Agreement, dated April 17, 2007, by and between NeoGenomics, Inc.
and Power3 Medical Products, Inc.
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-QSB, as filed
with the SEC on May 15, 2007
|
||
10.20
|
Convertible
Debenture, dated April 17, 2007, issued by Power3 Medical Products, Inc.
to NeoGenomics, Inc. in the principal amount of $200,000
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-QSB, as filed
with the SEC on May 15, 2007
|
||
10.21
|
Letter
Agreement, by and between NeoGenomics, Inc. and Noble International
Investments, Inc.
|
Incorporated
by reference to the Company’s Registration Statement on Form SB-2 as filed
with the SEC on July 6, 2007
|
||
10.22
|
Subscription
Documents
|
Incorporated
by reference to the Company’s Registration Statement on Form SB-2 as filed
with the SEC on July 6, 2007
|
||
10.23
|
Investor
Registration Right Agreement
|
Incorporated
by reference to the Company’s Registration Statement on Form SB-2 as filed
with the SEC on July 6, 2007
|
||
10.24
|
Credit
Agreement, dated February 1, 2008, by and between NeoGenomics, Inc., the
Nevada corporation, NeoGenomics, Inc., the Florida corporation, and
CapitalSource Finance LLC
|
Incorporated
by reference to the Company’s Report on Form 8-K for the SEC filed
February 7, 2008.
|
||
10.25
|
Employment
Agreement, dated March 12, 2008, between Neogenomics, Inc. and Mr. Robert
P. Gasparini
|
Incorporated
by reference to the Company’s Annual Report on Form 10-KSB as filed with
the SEC on April 14, 2008
|
||
10.26
|
Employment
Agreement, dated June 24, 2008, between Neogenomics, Inc. and Mr. Jerome
Dvonch
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2008, filed August 14, 2008
|
||
10.27
|
Common
Stock Purchase Agreement, dated November 5, 2008, between Neogenomics,
Inc., a Nevada corporation, and Fusion Capital Fund II,
LLC
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2008, filed November 7,
2008
|
||
10.28
|
Registration
Rights Agreement, dated November 5, 2008, between Neogenomics, Inc., a
Nevada corporation, and Fusion Capital Fund II, LLC
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2008, filed November 7,
2008
|
||
10.29
|
Master
Lease Agreement, dated November 5, 2008, between Neogenomics, Inc., a
Florida corporation, and Leasing Technologies International
Inc.
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2008, filed November 7,
2008
|
||
10.30
|
Guaranty
Agreement, dated November 5, 2008, between Neogenomics, Inc., a Nevada
corporation, and Leasing Technologies International, Inc.
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2008, filed November 7,
2008
|
Exhibit No.
|
Description of Exhibit
|
Location
|
||
10.31
|
First
Amendment to Revolving Credit and Security Agreement, dated November 3,
2008, among Neogenomics, Inc., a Florida corporation, Neogenomics, Inc., a
Nevada corporation, and CapitalSource Finance LLC
|
Incorporated
by reference to the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2008, filed November 7,
2008
|
||
14.1
|
NeoGenomics,
Inc. Code of Ethics for Senior Financial Officers and the Principal
Executive Officer
|
Incorporated
by reference to the Company’s Current Report on Form 8-K as filed with the
SEC on April 15, 2005
|
||
21.1
|
Subsidiaries
of Neogenomics, Inc., a Nevada corporation
|
Incorporated by reference to the Company's
Registration Statement on Form S-1 as filed with the SEC on November 28,
2008.
|
||
23.1
|
Consent
of Kingery & Crouse, P.A.
|
Provided
herewith
|
||
23.2
|
Consent
of Burton, Bartlett & Glogovac
|
Included
in Exhibit 5.1
|
||
24.1
|
Power
of Attorney
|
Included
in the signature pages to the Registration
Statement.
|
NEOGENOMICS,
INC.
|
||
By:
|
/s/ Robert P.
Gasparini
|
|
Name:
|
Robert
P. Gasparini
|
|
Title:
|
President
|
Signatures
|
Title(s)
|
Date
|
||
*
|
Chairman of the Board
|
January 22,
2009
|
||
Michael T. Dent, M.D.
|
||||
/s/ Robert P. Gasparini
|
President and Director
|
January 22,
2009
|
||
Robert P. Gasparini
|
(Principal Executive Officer)
|
|||
/s/ Steven C. Jones
|
Acting Principal Financial Officer and Director
|
January 22,
2009
|
||
Steven C. Jones
|
(Principal Financial Officer)
|
|||
/s/ Jerome J. Dvonch
|
Director of Finance
|
January 22,
2009
|
||
Jerome J. Dvonch
|
(Principal Accounting Officer)
|
|||
*
|
Director
|
January 22,
2009
|
||
George G. O’Leary
|
||||
*
|
Director
|
January 22,
2009
|
||
Peter M. Peterson
|
||||
*
|
Director
|
January 22,
2009
|
||
William J. Robison
|
||||
*
|
Director
|
January 22,
2009
|
||
Marvin E. Jaffe
|
*By: |
/s/Robert P.
Gasparini
|
January 22,
2009
|
|||
Robert P.
Gasparini
|
|||||
As Attorney-in-Fact
|